http://isagenixhealth.net/wp-content/uploads/2014/05/scientist-560x293.jpg  The Isagenix Research and Science team is pleased to announce that new findings from the weight-loss study performed at Skidmore College were presented at the American Society for Nutrition’s Scientific Sessions and Annual Meeting. The scientific poster presentation took place on April 30 at Experimental Biology conference in San Diego. In addition, the abstract of the study is now available online (click here) at the FASEB Journal website. The clinical study, which was initiated in 2013, built upon earlier research and provided increased validation through scientific support that use of Isagenix products is an advantageous method to support healthy weight loss, improve body composition, and improve cardiovascular risk factors. In the 10-week study, the scientists evaluated use of an Isagenix system incorporating high-protein meal replacements (IsaLean Shakes) and intermittent fasting (Cleanse Days) on 43 obese men and women. They measured several parameters including weight loss, body composition, plasma toxins (PCBs), physiological and metabolic markers including resting metabolic rate (RMR), and arterial status. In addition, the new study was the first to have measured an increase in circulating toxins from body fat as a result of weight loss. The Isagenix system is uniquely positioned as an intervention designed to provide nutritional support for the metabolic excretion of these stored toxins. After the 10 weeks on Isagenix products, the authors report that the subjects lost significant amounts of body weight and body fat. They also experienced a fat loss-associated increase of circulating toxins combined with elevated antioxidant protection—resulting from the nutritional intervention of the products. According to the lead author Paul Arciero, Ph.D., the results of the study so far have been “very exciting” with a few of the subjects seeing major transformations in terms of their weight loss and body composition. In addition, there were instances where there were reductions in weight while metabolism increased, along with improvements in insulin sensitivity. Because of the promising nature of the initial findings, Isagenix has now elected to extend the study beyond its original timeframe to include a weight-maintenance period. The study would be, then, the first to evaluate how well subjects are able to keep weight off with the Isagenix system. The study’s first author Eric Gumpricht, Ph.D., who presented the poster at the conference said, “I’ll just say ‘stay tuned’ because we have more science coming down the road. This is another step in providing validation for the scientific and medical community on how well designed and developed the Isagenix systems are for facilitating healthy weight loss, improving energy and performance, and healthy aging.”